Skip to main content
. Author manuscript; available in PMC: 2016 Apr 18.
Published in final edited form as: J Med Chem. 2015 Sep 17;58(19):7734–7748. doi: 10.1021/acs.jmedchem.5b00686

Figure 6. Antitumor effects against human glioma tumor xenografts in vivo.

Figure 6

(A) Mice bearing U251MG subcutaneous tumor xenografts were administered 6 or 22 via oral gavage, 2 mg/kg or vehicle (1% DMSO) every other day for 33 days. Tumor sizes, measured every 3 days, were converted to tumor volumes and plotted against days of treatment; and (B) immunoblots of pStat3, Stat3 or GAPDH in tumor tissue lysates prepared from control and treated mice. Positions of proteins in gel are labeled; control lanes (c) represent tissue lysates prepared from mice treated with 1% DMSO. Values, mean ± S.D., n=6. * - <0.05.